(Q35377275)

English

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib (English)

1 reference

Europe PubMed Central

8 August 2017

1 reference

based on heuristic

inferred from title

author name string

Kevin R Kelly

1

1 reference

Europe PubMed Central

8 August 2017

Jeffrey Ecsedy

2

1 reference

Europe PubMed Central

8 August 2017

Ernest Medina

3

1 reference

Europe PubMed Central

8 August 2017

Devalingam Mahalingam

4

1 reference

Europe PubMed Central

8 August 2017

Swaminathan Padmanabhan

5

1 reference

Europe PubMed Central

8 August 2017

Steffan T Nawrocki

6

1 reference

Europe PubMed Central

8 August 2017

Francis J Giles

7

1 reference

Europe PubMed Central

8 August 2017

Jennifer S Carew

8

1 reference

Europe PubMed Central

8 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2011

1 reference

Europe PubMed Central

8 August 2017

Journal of Cellular and Molecular Medicine

1 reference

Europe PubMed Central

8 August 2017

15

1 reference

Europe PubMed Central

8 August 2017

2057-2070

1 reference

Europe PubMed Central

8 August 2017

10

1 reference

Europe PubMed Central

8 August 2017

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Imatinib resistance in CML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Final stages of cytokinesis and midbody ring formation are controlled by BRUCE

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Roles of Aurora kinases in mitosis and tumorigenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Aurora-A - a guardian of poles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Intrinsic tumour suppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

A human IAP-family gene, apollon, expressed in human brain cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4394217

12 July 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2010.01218.X

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2010.01218.X

21 January 2018

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2010.01218.X

21 January 2018

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2010.01218.X

21 January 2018

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21091633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An Apollon vista of death and destruction

1 reference

https://pubmed.ncbi.nlm.nih.gov/21091633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

https://pubmed.ncbi.nlm.nih.gov/21091633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21091633

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1582-4934.2010.01218.X

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35377275&oldid=1861512381"